Cargando…

Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study

This retrospective cohort study was conducted to estimate incidence rates of new-onset hypertension in adult cancer patients identified from the Varian Medical Oncology outpatient database. Incidence rates of increasing levels of hypertension severity were calculated overall and for periods of chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraeman, Kathy H., Nordstrom, Beth L., Luo, Weixiu, Landis, Sarah H., Shantakumar, Sumitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876828/
https://www.ncbi.nlm.nih.gov/pubmed/24455206
http://dx.doi.org/10.1155/2013/379252
_version_ 1782297548963184640
author Fraeman, Kathy H.
Nordstrom, Beth L.
Luo, Weixiu
Landis, Sarah H.
Shantakumar, Sumitra
author_facet Fraeman, Kathy H.
Nordstrom, Beth L.
Luo, Weixiu
Landis, Sarah H.
Shantakumar, Sumitra
author_sort Fraeman, Kathy H.
collection PubMed
description This retrospective cohort study was conducted to estimate incidence rates of new-onset hypertension in adult cancer patients identified from the Varian Medical Oncology outpatient database. Incidence rates of increasing levels of hypertension severity were calculated overall and for periods of chemotherapy exposure and nonexposure. Cox models sought predictors of new-onset hypertension severity among baseline and chemotherapy exposure variables. New-onset hypertension was observed in about one-third of 25,090 patients with various cancer types. The incidence rates (IR) of severe and crisis-level hypertension, respectively, were the highest in patients with gastric (18.5 cases per 100 person-years (PY), 5.6 per 100 PY) and ovarian cancer (20.2 per 100 PY, 4.8 per 100 PY). The highest IR of moderate hypertension was observed in patients with renal cancer (46.7 per 100 PY). Across all cancers, chemotherapy exposure was associated with a 2–3.5-fold increase in risk of any degree of hypertension compared to periods of no chemotherapy; higher hypertension levels showed greater variability in relative risks by type and line of therapy but indicated an overall increase associated with chemotherapy exposure. These results help to elucidate the factors influencing HTN among cancer patients and the incidence of HTN relative to chemotherapy exposure.
format Online
Article
Text
id pubmed-3876828
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38768282014-01-16 Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study Fraeman, Kathy H. Nordstrom, Beth L. Luo, Weixiu Landis, Sarah H. Shantakumar, Sumitra Int J Hypertens Research Article This retrospective cohort study was conducted to estimate incidence rates of new-onset hypertension in adult cancer patients identified from the Varian Medical Oncology outpatient database. Incidence rates of increasing levels of hypertension severity were calculated overall and for periods of chemotherapy exposure and nonexposure. Cox models sought predictors of new-onset hypertension severity among baseline and chemotherapy exposure variables. New-onset hypertension was observed in about one-third of 25,090 patients with various cancer types. The incidence rates (IR) of severe and crisis-level hypertension, respectively, were the highest in patients with gastric (18.5 cases per 100 person-years (PY), 5.6 per 100 PY) and ovarian cancer (20.2 per 100 PY, 4.8 per 100 PY). The highest IR of moderate hypertension was observed in patients with renal cancer (46.7 per 100 PY). Across all cancers, chemotherapy exposure was associated with a 2–3.5-fold increase in risk of any degree of hypertension compared to periods of no chemotherapy; higher hypertension levels showed greater variability in relative risks by type and line of therapy but indicated an overall increase associated with chemotherapy exposure. These results help to elucidate the factors influencing HTN among cancer patients and the incidence of HTN relative to chemotherapy exposure. Hindawi Publishing Corporation 2013 2013-12-16 /pmc/articles/PMC3876828/ /pubmed/24455206 http://dx.doi.org/10.1155/2013/379252 Text en Copyright © 2013 Kathy H. Fraeman et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fraeman, Kathy H.
Nordstrom, Beth L.
Luo, Weixiu
Landis, Sarah H.
Shantakumar, Sumitra
Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
title Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
title_full Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
title_fullStr Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
title_full_unstemmed Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
title_short Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
title_sort incidence of new-onset hypertension in cancer patients: a retrospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876828/
https://www.ncbi.nlm.nih.gov/pubmed/24455206
http://dx.doi.org/10.1155/2013/379252
work_keys_str_mv AT fraemankathyh incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy
AT nordstrombethl incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy
AT luoweixiu incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy
AT landissarahh incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy
AT shantakumarsumitra incidenceofnewonsethypertensionincancerpatientsaretrospectivecohortstudy